Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
- PMID: 11207510
- DOI: 10.1046/j.1365-2036.2001.00937.x
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
Abstract
Aim: To update previous overviews of placebo-controlled double-blind trials assessing the efficacy and tolerance of smooth muscle relaxants in irritable bowel syndrome. METHODS AND TRIALS: A total of 23 randomized clinical trials were selected for meta-analyses of their efficacy and tolerance. Six drugs were analysed: cimetropium bromide (five trials), hyoscine butyl bromide (three trials), mebeverine (five trials), otilium bromide (four trials), pinaverium bromide (two trials) and trimebutine (four trials). The total number of patients included was 1888, of which 945 received an active drug and 943 a placebo.
Results: The mean percentage of patients with global improvement was 38% in the placebo group (n=925) and 56% in the myorelaxant group (n=927), in favour of myorelaxants with a mean odds ratio of 2.13, P < 0.001 (95% CI: 1.77--2.58) and a mean risk difference of 22% P < 0.001 (95% CI: 13--32%). The percentage of patients with pain improvement was 41% in the placebo group (n=568) and 53% in the myorelaxant group (n=567): odds ratio 1.65, P < 0.001 (95% CI: 1.30--2.10) and risk difference 18%, P < 0.001 (95% CI: 7--28%). There was no significant difference for adverse events.
Conclusion: Myorelaxants are superior to placebo in the management of irritable bowel syndrome.
Comment in
- ACP J Club. 2001 Sep-Oct;135(2):53
Similar articles
-
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.Aliment Pharmacol Ther. 1994 Oct;8(5):499-510. doi: 10.1111/j.1365-2036.1994.tb00322.x. Aliment Pharmacol Ther. 1994. PMID: 7865642
-
Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.Gut. 1990 Mar;31(3):355-8. doi: 10.1136/gut.31.3.355. Gut. 1990. PMID: 2182401 Free PMC article. Clinical Trial.
-
Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.Aliment Pharmacol Ther. 1998 Oct;12(10):1003-10. doi: 10.1046/j.1365-2036.1998.00397.x. Aliment Pharmacol Ther. 1998. PMID: 9798806 Clinical Trial.
-
Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis.Rev Gastroenterol Mex. 2012 Apr-Jun;77(2):82-90. doi: 10.1016/j.rgmx.2012.04.002. Epub 2012 Jun 5. Rev Gastroenterol Mex. 2012. PMID: 22672854 Review.
-
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.World J Gastroenterol. 2010 Feb 7;16(5):547-53. doi: 10.3748/wjg.v16.i5.547. World J Gastroenterol. 2010. PMID: 20128021 Free PMC article. Review.
Cited by
-
Irritable bowel syndrome: a review and update.Clin Colon Rectal Surg. 2012 Mar;25(1):46-52. doi: 10.1055/s-0032-1301759. Clin Colon Rectal Surg. 2012. PMID: 23449495 Free PMC article.
-
Drug development for the irritable bowel syndrome: current challenges and future perspectives.Front Pharmacol. 2013 Feb 1;4:7. doi: 10.3389/fphar.2013.00007. eCollection 2013. Front Pharmacol. 2013. PMID: 23378837 Free PMC article.
-
Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats.World J Gastroenterol. 2003 Mar;9(3):557-61. doi: 10.3748/wjg.v9.i3.557. World J Gastroenterol. 2003. PMID: 12632518 Free PMC article.
-
Treatment of Excessive Intestinal Gas.Curr Treat Options Gastroenterol. 2004 Aug;7(4):299-305. doi: 10.1007/s11938-004-0016-2. Curr Treat Options Gastroenterol. 2004. PMID: 15238205
-
Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. World J Gastroenterol. 2014. PMID: 24944467 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical